"The
Report PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and
Market Analysis to 2023 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Renal cell carcinoma (RCC) is
among the 10 most frequently occurring cancers in Western countries.
The RCC market is currently dominated by anti-angiogenic agents and
tyrosine kinase inhibitors (TKIs) in particular, but it will
experience dramatic changes over the forecast period as patents
expire and promising new therapies enter the market. A large share of
the RCC market is currently dominated by a few large companies, but
they will struggle to retain these shares as they are joined by new
entrants. One of these new entrants, Opdivo, is expected to have the
largest market share by 2023. The different lines of treatment will
offer up different battlegrounds and niches for companies, large and
small, to compete for. The battle for the first-line of therapy is
expected to be fierce, with three programmed death protein 1
(PD-1)/programmed death ligand 1 (PD-L1)-containing combination
therapies backed by large companies lining up to compete. Out of this
competition, new standards of care are expected to emerge for the
different lines of treatment. There will also be a number of unmet
needs still remaining at the end of the forecast period, and with
that, the opportunity for pipeline drugs to carve out a niche in the
RCC space.
View Report At
:http://www.marketresearchreports.biz/analysis/761833
Highlights
Key Questions Answered
- The RCC market is marked by
the presence of a number of unmet needs. What are the main unmet
needs in this market? Will the drugs under development fulfil the
unmet needs of RCC market?
- The late-stage RCC pipeline
has therapies targeting different lines of therapy. Which drugs will
have the biggest impact in each RCC setting? Which of these drugs
will have the highest peak sales at the highest CAGR, and why?
- Current therapies used to
treat RCC include tyrosine kinase inhibitors and mTOR inhibitors.
What will be the impact of the patent expiry of the current standard
of care? How will the advent of new therapies change the drug
treatment landscape for RCC? How will new drug combinations change
the treatment paradigm of RCC? What are the key drivers and barriers
to this change?
Key Findings
- The main drivers of the
growth of the RCC market will be the launch of Opdivo in second-line
setting and PD-1 modulator combinations in the first-line setting.
GlobalData forecasts significant patient uptake for Opdivo, which
will supersede tyrosine kinase inhibitors and mTOR inhibitors to
become the SoC in second-line setting.
- The approval of immunotherapy
in monotherapy or in combination with other agents will partially
fulfil key unmet needs in the RCC space: however, many of these unmet
needs will still remain even after these agents are launched.
- Another driver of the RCC
market is the increasing incidence of RCC cases within the 8MM. The
biggest constrainer of the RCC market is the launch of generics of
tyrosine kinase inhibitors currently established as standard of care
in most markets.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/761833
Scope
- Overview of RCC, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized RCC therapeutics
market revenue, average cost of therapy and treatment usage pattern
data from 2013 and forecast for ten years to 2023.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, clinical trial mapping and implications for the RCC
therapeutics market.
- Pipeline analysis:
comprehensive data split across different phases, emerging novel
trends under development, and detailed analysis of late-stage
pipeline drugs.
- Analysis of the current and
future market competition in the global RCC therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global RCC
therapeutics market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global RCC
therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global RCC therapeutics market from 2013-2023.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table
of Contents
1
Table of Contents 8
1.1
List of Tables 15
1.2
List of Figures 21
2
Introduction 24
2.1
Catalyst 24
2.2
Related Reports 24
2.3
Upcoming Related Reports 25
3
Disease Overview 26
3.1
Etiology and Pathophysiology 26
3.1.1
Etiology 26
3.1.2
Pathophysiology 26
3.2
Clinical Staging 27
3.3
Symptoms 28
3.4
Prognostic Models 29
3.5
Potential Biomarkers 30
4
Epidemiology 31
4.1
Disease Background 31
4.2
Risk Factors and Comorbidities 31
4.3
Global Trends 33
4.3.1
Incidence 33
4.3.2
Survival Rates for RCC - 8MM 35
4.4
Forecast Methodology 36
4.4.1
Sources Used 38
4.4.2
Sources Not Used 41
4.4.3
Forecast Assumptions and Methods for RCC Diagnosed Incident Cases 41
4.4.4
Forecast Assumptions and Methods for RCC Five-Year Diagnosed
Prevalent Cases 42
4.4.5
Forecast Assumptions and Methods for RCC by Clinical Stage at
Diagnosis 43
4.5
Epidemiological Forecast of RCC (2013-2023) 44
4.5.1
Diagnosed Incident Cases of RCC 44
4.5.2
Age-Specific Diagnosed Incident Cases of RCC 45
4.5.3
Sex-Specific Diagnosed Incident Cases of RCC 47
4.5.4
Age-Standardized Diagnosed Incidence of RCC 49
4.5.5
Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 51
4.5.6
Five-Year Diagnosed Prevalent Cases of RCC 52
4.6
Discussion 53
4.6.1
Epidemiological Forecast Insight 53
4.6.2
Limitations of the Analysis 54
4.6.3
Strengths of the Analysis 54
5
Disease Management 56
5.1
Diagnosis and Treatment Overview 56
5.1.1
Screening and Diagnosis 56
5.1.2
Surgical Management of RCC 56
5.1.3
Treatment Guidelines and Leading Prescribed Drugs 57
5.1.4
Clinical Practice 59
5.2
US 64
5.2.1
Diagnosis and Surgical Management 64
5.2.2
Clinical Practice (Drug Treatment) 65
5.3
France 66
5.3.1
Diagnosis and Surgical Management 66
5.3.2
Clinical Practice (Drug Treatment) 67
5.4
Germany 67
5.4.1
Diagnosis and Surgical Management 68
5.4.2
Clinical Practice (Drug Treatment) 68
5.5
Italy 69
5.5.1
Diagnosis and Surgical Management 69
5.5.2
Clinical Practice (Drug Treatment) 70
5.6
Spain 71
5.6.1
Diagnosis and Surgical Management 71
5.6.2
Clinical Practice (Drug Treatment) 72
Read
our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment